Therapeutic challenges of attention-deficit hyperactivity disorder with substance use disorders

Expert Review of Neurotherapeutics

Volumn 6, Issue 4, 2006, Pages 541-549

  Bukstein, Oscar G ^a  

^a UNIVERSITY OF PITTSBURGH   (United States)

Author keywords

Attention deficit and hyperactivity disorder; Diversion; Psychopharmacology; Substance use disorders

Indexed keywords

AMFEBUTAMONE; AMPHETAMINE; AMPHETAMINE DERIVATIVE; ATOMOXETINE; COCAINE; DEXAMPHETAMINE; DEXMETHYLPHENIDATE; DOPAMINE RECEPTOR; METHYLPHENIDATE; MODAFINIL; PRESYNAPTIC RECEPTOR; PSYCHOSTIMULANT AGENT; TRICYCLIC ANTIDEPRESSANT AGENT; VENLAFAXINE;

ADULTHOOD; ATTENTION DEFICIT DISORDER; CHILDHOOD; CLINICAL TRIAL; COMORBIDITY; CONTROLLED DRUG RELEASE; DAYTIME SOMNOLENCE; DISEASE ASSOCIATION; DRUG ABUSE; DRUG CLEARANCE; DRUG EFFICACY; DRUG MECHANISM; DRUG RECEPTOR BINDING; HUMAN; MENTAL DISEASE; NARCOLEPSY; NONHUMAN; REVIEW; SUBSTANCE ABUSE; SUSTAINED DRUG RELEASE;

ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY; HUMANS; SUBSTANCE-RELATED DISORDERS;

EID: 33646806068     PISSN: 14737175     EISSN: 17448360     Source Type: Journal    
DOI: 10.1586/14737175.6.4.541     Document Type: Review

References (94)

1. Barkley R. Attention-deficit hyperactivity disorder, In: A handbook for diagnosis and treatment, Third Edition. Guilford Press, NY, USA (2005).
2. Weiss G, Hechtman L, Milroy T, Perlman T. Psychiatric status of hyperactives as adults: a controlled prospective 15-year follow-up of 63 hyperactive children. J. Am. Acad. Child Adolesc. Psychiatry 24, 211-220 (1985).
3. Barkley RA, Biederman J. Toward a broader definition of the age-of-onset criterion for attention-deficit hyperactivity disorder. J. Am. Acad. Child Adolesc. Psychiatry 36, 1204-1210 (1997).
4. Bukstein OG, American Academy of Child and Adolescent Psychiatry. Practice parameters for the assessment and treatment of children and adolescents with substance use disorders. J. Am. Acad. Child Adolesc. Psychiatry 44, 609-621 (2005).
5. Kessler RC, Chiu WT, Demler O, Walters EE. Prevalence, severity, and comorbidity of 12-month DSM-IV disorders in the National Comorbidity Survey Replication. Arch. Gen. Psychiatry 62(6), 617-627 (2005).
6. Levin FR, Evans SM, McDowell DM. Methylphenidate treatment for cocaine abusers with adult attention-deficit hyperactivity disorder: a pilot study. J. Clin. Psychiatry 59, 300-305 (1998).
7. King VL, Brooner RK, Kidorf MS. Attention deficit hyperactivity disorder and treatment outcome in opioid abusers entering treatment. J. Nerv. Ment. Dis. 187, 487-495 (1999).
8. Schubiner H, Tzelepis A, Milberger S. Prevalence of attention-deficit hyperactivity disorder and conduct disorder among substance abusers. J. Clin. Psychiatry 61, 244-251 (2000).
9. DeMilio L. Psychiatric syndromes in adolescent substance abusers. Am. J. Psychiatry 146, 1212-1214 (1989).
10. Milin R, Halikas JA, Meller JE et al. Psychopathology among substance abusing juvenile offenders. J. Am. Acad. Child Adolesc. Psychiatry 30(4), 569-574 (1991).
11. Molina BSG, Bukstein OG, Lynch KG. ADHD and conduct disorder symptomatology in adolescents with alcohol use disorder. Psychol. Addict. Behav. 16(2), 161-164 (2002).
12. Thompson LL, Riggs PD, Mikulich SK et al. Contribution of ADHD symptoms to substance problems and delinquency in conduct-disordered adolescents. J. Abnorm. Child Psychol. 24, 325-347 (1996).
13. Goodwin DW, Schulsinger F, Hermansen L et al. Alcoholism and the hyperactive child syndrome. J. Nerv. Ment. Dis. 160(5), 349-353 (1975).
14. Wilens T, Spencer T, Biederman J. Are attention-deficit/hyperactivity disorder and the psychoactive substance use disorders really related? Harv. Rev. Psychiatry 3, 260-262 (1995).
15. Mannuzza S, Klein RG, Bessler A et al. Adult psychiatric status of hyperactive boys grown up. Am. J. Psychiatry 155, 493-498 (1998).
16. Hechtman L, Weiss G. Controlled prospective fifteen year follow-up of hyperactives as adults: nonmedical drug and alcohol use and anti-social behaviour. Can. J. Psychiatry 31, 557-567 (1986).
17. Biederman J, Monuteaux MC, Mick E et al. Young adult outcome of attention deficit hyperactivity disorder: a controlled 10-year follow-up study. Psychol. Med. 36, 167-179 (2006).
18. Schubiner H, Tzelepis A, Milberger S et al. Prevalence of ADHD and conduct disorder among substance abusers. J. Clin. Psychiatry 61, 244-251 (2000).
19. Wilens T. Alcohol and other drug use and attention-deficit/hyperactivity disorder. Alcohol Health Res. World 22(2), 127-130 (1998).
20. Wilens TE, Biederman J, Mick E et al. Attention deficit hyperactivity disorder (ADHD) is associated with early onset substance use disorders. J. Nerv. Ment. Dis. 185, 475-482 (1997).
21. McGough JJ, Smalley SL, McCracken JT et al. Psychiatric comorbidity in adult attention deficit hyperactivity disorder: findings from multiplex families. Am. J. Psychiatry 162(9), 1621-1627 (2005).
22. Carroll KM, Rounsaville BJ. History and significance of childhood attention deficit disorder in treatment-seeking cocaine abusers. Compr. Psychiatry 34, 75-82 (1993).
23. Levin FR, Evans SM, McDowell D, Kleber HD. Methylphenidate treatment for cocaine abusers with adult attentiondeficit/hyperactivity disorder: a pilot study. J. Clin. Psychiatry 58, 1-21 (1997).
24. Barkley RA, Fischer M, Smallish L, Fletcher K. Young adult follow-up of hyperactive children: antisocial activities and drug use. J. Child Psychol. Psychiatry 45, 195-211 (2004).
25. Gittelman R, Mannuzza S, Shenker R, Bonagura N. Hyperactive boys almost grown up, I: psychiatric status. Arch. Gen. Psychiatry 42, 937-947 (1985).
26. Lynskey MT, Fergusson DM. Childhood conduct problems and attention deficit behaviours and adolescent alcohol, tobacco and illicit drug use. J. Abnorm. Child Psychol. 23, 281-302 (1995).
27. Disney ER, Elkins IJ, McGue M et al. Effects of ADHD, conduct disorder, and gender on substance use and abuse in adolescence. Am. J. Psychiatry 156, 1515-1521 (1999).
28. Greenbaum PE, Prange ME, Friedman RM et al. Substance abuse prevalence and comorbidity with other psychiatric disorders among adolescents with severe emotional disturbances. J. Am. Acad. Child Adolesc. Psychiatry 30, 575-583 (1991).
29. Molina BSG, PelhamWE. Childhood predictors of adolescent substance use in a longitudinal study of children with ADHD. J. Abnorm. Psychol. 112(3), 497-507 (2003).
30. Loeber R, Brinthaupt VP, Green SM. Attention deficits, impulsivity, and hyperactivity with or without conduct problems: relationships to delinquency and unique contextual factors. In: Behavior Disorders of Adolescence: Research, Intervention, and Policy in Clinical and School Settings. McMahon RJ, Peters RD (Eds). Plenum, NY, USA. 39-61 (1990).
31. Moffitt TE. Juvenile delinquency and attention deficit disorder: boys developmental trajectories from age 3 to age 15. Child Dev. 61, 893-910 (1990).
32. Adler L, Cohen J. Diagnosis and evaluation of adults with attention-deficit/hyperactivity disorder. Psychiatr. Clin. North Am. 27, 187-201 (2004).
33. Collett BR, Ohan JL, Myers KM. Ten-year review of rating scales. v: scales assessing attention-deficit/hyperactivity disorder. J. Am. Acad. Child Adolesc. Psychiatry 42(9), 1015-1037 (2003).
34. Conners CK, Erhardt JN, Epstein D et al. Conners adult self-rating of ADHD symptoms in adults I: factor structure and normative data. J. Atten. Disord. 3(3), 141-151 (1999).
35. Millstein RB, Wilens TE, Biederman J, Spencer TJ. Presenting ADHD symptoms and subtypes in clinically referred adult with ADHD. J. Atten. Disord. 2, 159-166 (1997).
36. Wilens TE, Haight BR, Horrigan JP et al. Bupropion XL in adults with attention-deficit/hyperactivity disorder: a randomized, placebo-controlled study. Biol. Psychiatry 57(7), 793-801(2005).
37. Spencer T, Biederman J, Wilens T. Stimulant treatment of adult attention-deficit/hyperactivity disorder. Psychiatr. Clin. North Am. 27(2), 361-372 (2004).
38. Robbins TW, Everitt BJ. Drug addiction: bad habits add up. Nature 398, 567-570 (1999).
39. Huss M, Lehmkuhl U. Methylphenidate and substance abuse: a review of pharmacology, animal and clinical studies. J. Atten. Disord. 6, 565-571 (2002).
40. Kollins SH, MacDonald EK, Rush CR. Assessing the abuse potential of methylphenidate in nonhuman and human subjects: a review. Pharmacol. Biochem. Behav. 68, 611-627 (2001).
41. Volkow ND, Ding Y, Fowler JS et al. Is methylphenidate like cocaine? Studies on their pharmacokinetics and distribution in the human brain. Arch. Gen. Psychiatry 52, 456-463 (1995).
42. Volkow N, Wang G, Fowler J et al. Association of methylphenidate-induced craving with changes in right striatoorbitofrontal metabolism in cocaine abusers: implications in addictions. Am. J. Psychiatry 156(1), 19-26 (1999).
43. Volkow ND, Wang GJ, Fowler JS et al. Therapeutic doses of oral methylphenidate significantly increase extracellular dopamine in human brain. J. Neurosci. 21, 1-5 (2001).
44. Volkow ND, Wang GJ, Fowler JS et al. Relationship between blockade of dopamine transporters by oral methylphenidate and the increases in extracellular dopamine. Therapeutic implications. Synapse 43(3), 181-187 (2002).
45. Volkow ND, Wang GJ, Fowler JS et al. Dopamine transporter occupancies in the human brain induced by therapeutic doses of oral methylphenidate. Am. J. Psychiatry 155, 1325-1331 (1998).
46. Jaffe SL. Failed attempts at intranasal abuse of concerta. J. Am. Acad. Child Adolesc. Psychiatry 41(1), 5 (2002).
47. Ciccone PE. Attempted abuse of Concerta®. J. Am. Acad. Child Adolesc. Psychiatry 41, 756 (2002).
48. Grabowski J, Roache JD, Schmitz JM, Rhoades H, Creson D, Korszun A. Replacement medication for cocaine dependence. Methylphenidate. J. Clin. Psychopharmacol. 17(6), 485-488 (1997).
49. Shearer J, Wodak A, Mattick R et al. Pilot randomized controlled study of dexamphetamine substitution for amphetamine dependence. Addiction 96, 1289-1296 (2001).
50. Michelson D, Adler L, Spencer T et al. Atomoxetine in adults with ADHD: two randomized, placebo-controlled studies. Biol. Psychiatry 53, 112-120 (2003).
51. Michelson D, Allen AJ, Busner J et al. Once-daily atomoxetine treatment for children and adolescents with attention deficit hyperactivity disorder: a randomized, placebo-controlled study. Am. J. Psychiatry 159, 1896-1901 (2002).
52. Bymaster FP, Katner JS, Nelson DL et al. Atomoxetine increases extracellular levels of norepinephrine and dopamine in prefrontal cortex of rat: a potential mechanism for efficacy inattention deficit/hyperactivity disorder. Neuropsychopharmacology 27, 699-711 (2002).
53. Heil SH, Holmes HW, Bickel WK et al. Comparison of the subjective, physiological, and psychomotor effects of atomoxetine and methylphenidate in light drug users. Drug Alcohol Depend. 67(2), 149-156 ( 2002).
54. Davidson JT, Connor KM. Bupropion sustained release: a therapeutic overview. J. Clin. Psychiatry 58(Suppl. 4), 25-31 (1998).
55. Ferris RM, Cooper BR, Maxwell RA. Studies of bupropion's mechanism of antidepressant activity. J. Clin. Psychiatry 44, 74-78 (1983).
56. Griffith JD, Carranza J, Griffith C, Miller LI. Bupropion: clinical essay for amphetaminelike potential. J. Clin. Psychiatry 44, 206-208 (1983).
57. Hurt RD, Sachs PPL, Glover ED et al. A comparison of sustained-release bupropion and placebo for smoking cessation. N. Engl. J. Med. 337, 1195-1202 (1997).
58. Goldstein MG. Bupropion sustained release and smoking cessation. J. Clin. Psychiatry 59, 66-72 (1998).
59. Dackis CA, Lynch KG, Yu E et al. Modafinil and cocaine: a double-blind, placebo-controlled drug interaction study. Drug Alcohol Depend. 70, 29-37 (2003).
60. Turner DC, Robbins TW, Clark L et al. Cognitive enhancing effects of modafinil in healthy volunteers. Psychopharmacology 165, 260-269 (2003).
61. Turner DC, Clark L, Dowson J et al. Modafinil improves cognition and response inhibition in adult attention deficit/hyperactivity disorder. Biol. Psychiatry 55, 1031-1040 (2004).
62. Dackis CA, Kampman KM, Lynch KG et al. A double-blind, placebo-controlled trial of modafinil for cocaine dependence. Neuropsychopharmacology 30, 205-211 (2005).
63. Rugino TA, Copley TC. Effects of modafinil in children with attention-deficit/hyperactivity disorder: an open-label study. J. Am. Acad. Child Adolesc. Psychiatry 40(2), 230-235 (2001).
64. Biederman J, Swanson JM, Wigal SB et al. Efficacy and safety of modafinil film-coated tablets in children and adolescents with attention-deficit/ hyperactivity disorder: results of a randomized, double-blind, placebo-controlled, flexible-dose study. Pediatrics 116, E777-E784 (2005).
65. Swanson JM, Greenhill LL, Lopez FA et al. Modafinil film-coated tablets in children and adolescents with attention-deficit/hyperactivity disorder: results of a randomized, double-blind, placebo-controlled, fixed-dose study followed by abrupt discontinuation. J. Clin. Psychiatry 67, 137-147 (2006).
66. Myrick H, Malcolm R, Taylor B, LaRowe S. Modafinil: preclinical, clinical, and post-marketing surveillance-a review of abuse liability issues. Ann. Clin. Psychiatry 16(2), 101-109 (2004).
67. Johnston L, O'Malley P, Bachman J. Monitoring the Future National Survey Results on Drug Use, 1975-2000. Vol. I: Secondary School Students NIH Publication No. 01-4924, National Institute on Drug Abuse, MD, USA (2001).
68. Indiana Prevention Resource Center Survey. Alcohol, Tobacco, and Other Drug Use by Indiana Children and Adolescents Bloomington, IN. Indiana University, USA (1998).
69. Addiction Research Foundation. The Ontario Study Drug Use Survey: 1977-1995 Toronto, Ontario. Arkansas, Canada. (1995).
70. Gordon SM, Tulak F, Troncale J. Prevalence and characteristics of adolescents patients with co-occurring ADHD and substance dependence. J. Addict. Dis. 23(4), 31-40 (2004).
71. Williams RJ, Goodale LA, Shay-Fiddler MA, Gloster SP, Chang SY. Methylphenidate and dextroamphetamine abuse in substance-abusing adolescents. Am. J. Addict. 13(4), 381-389 (2004).
72. McCabe SE, Teter CJ, Boyd CJ. The use, misuse and diversion of prescription stimulants among middle and high school students. Subst. Use Misuse 39, 1095-1116 (2004).
73. McCabe SE, Knight JR, Teter CJ, Wechsler H. Nonmedical use of prescription stimulants among US college students: prevalence and correlates from a national survey. Addiction 100, 96-106 (2005).
74. Teter CJ, McCabe SE, Cranford JA, Boyd CJ, Guthrie SK. Prevalence and motives for illicit use of prescription stimulants in an undergraduate student sample. J. Am. Coll. Health 53, 253-262 (2005).
75. McCabe SE, Boyd CJ. Sources of prescription drugs for illicit use. Addcit. Behav. 30, 1342-1350 (2005).
76. National Institute on Drug Abuse (NIDA) Community Epidemiology Work Group (CEWG). Epidemiologic Trends In Drug Abuse. NIH, Washington, DC, USA (1995).
77. Jaffe SL. Intranasal abuse of prescribed methylphenidate by an alcohol and drug abusing adolescent with ADHD. J. Am. Acad. Child Adolesc. Psychiatry 30, 773-775 (1991).
78. Wilens TE, Faraone SV, Biederman J et al. Does stimulant therapy of attention-deficit/hyperactivity disorder beget later substance abuse? A meta-analytic review of the literature. Pediatrics 111, 179-185 (2003).
79. Faraone SV, Wilens T. Does stimulant treatment lead to substance use disorders? J. Clin. Psychiatry 64(Suppl. 11), 9-13 (2003).
80. Biederman J, Wilens T, Mick E et al. Is ADHD a risk for psychoactive substance use disorder? Findings from a four-year follow-up study. J. Am. Acad. Child Adolesc. Psychiatry 36, 21-29 (1997).
81. Pelham WE, Molina BS, Meichenbaum D, Gnagy E, Greenhouse J. Stimulant effects on long term outcomes in ADHD individuals. Presentation at: 43rd Annual New Clinical Drug Evaluation Unit Meeting, Boca Raton, FL, USA (2003).
82. Levin FR, Evans SM, Brooks DJ et al. Treatment of methadone-maintained patients with adult ADHD: double-blind comparison of methylphenidate, bupropion and placebo. Drug Alcohol Depend. 81, 137-148 (2006).
83. Riggs PD, Hall SK, Mikulich-Gilbertson SK, Lohman M, Kayser A. A randomized controlled trial of pemoline for attention-deficit/hyperactivity disorder in substanceabusing adolescents. J. Am. Acad. Child Adolesc. Psychiatry 43(4), 420-429 (2004).
84. Schubiner H, Saules KK, Arfken CL et al. Double-blind placebo-controlled trial of methylphenidate in the treatment of adult ADHD patients with comorbid cocaine dependence. Exp. Clin. Psychopharmacol. 10(3), 286-294 (2002).
85. Levin FR, Evans SM, McDowell DM, Brooks DJ, Nunes E. Bupropion treatment for cocaine abuse and adult attention-deficit/hyperactivity disorder. J. Addict. Dis. 21(2), 1-16 (2002).
86. Upadhyaya HP, Brady KT, Sethuraman G, Sonne SC, Malcolm R. Venlafaxine treatment of patients with comorbid alcohol/cocaine abuse and attention-deficit/hyperactivity disorder: a pilot study. J. Clin. Psychopharmacol. 21(1), 116-118 (2001).
87. Prince J, Wilens T, Waxmonsky J et al. An open study of sustained-release bupropion in adults with ADHD and substance use disorders. In: Scientific Proceedings of the American Psychiatric Association: New Clinical Drug Evaluation Unit (NCDEU), NR, USA. 222 (2002).
88. Riggs PD, Leon SL, Mikulich SK, Pottle LC. An open trial of bupropion for ADHD in adolescents with substance abuse disorders and conduct disorder. J. Am. Acad. Child Adolesc. Psychiatry 37(12), 1271-1278 (1998).
89. Wilens TE, Monuteaux MC, Snyder LE et al. The clinical dilemma of using medications in substance-abusing adolescents and adults with attention-deficit/hyperactivity disorder: what does the literature tell us? J. Child Adolesc. Psychopharmacol. 15, 787-779 (2005).
90. Drug Enforcement Administration. Methylphenidate review document. Washington, DC DEA Office of Diversion Control, Drug and Chemical Evaluation Section (1995).
91. Langer DH, Sweeney KP, Bartenbach DE, Davis PM, Menander KB. Evidence of lack of abuse or dependence following pemoline treatment: results of a retrospective survey. Drug Alcohol Depend. 17, 213-227 (1986).
92. Riggs PD. Clinical approach to treatment of ADHD in adolescents with substance use disorders and conduct disorder. J. Am. Acad. Child Adolesc. Psychiatry 37(3), 331-332 (1998).
93. Adler LA, Kessler RC, Spencer T. The adult ADHD self-report scale (ASRS-v1.1) symptom checklist: World Health Organisation 2002 www.med.nyu.edu/psych/assets/adhdscreen18.pdf
94. Drug Enforcement Administration (DEA) 2006. www.usdoj.gov/dea/pubs/ cngrtest/ct051600.htm